{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269538","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.473510+00:00","generated_at":"2026-05-16T23:37:05.501733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunome Q3 net loss $57.5M; cash $272.6M; varegacestat data due by year-end","bullets":["Net loss of $57.5M for Q3 2025; cash and equivalents $272.6M.","Expects topline data from Phase 3 RINGSIDE (varegacestat) before end of 2025.","IM-1021 shows objective responses in B-cell lymphoma; initial data in 2026.","HC74 payload overcomes multi-drug resistance in preclinical models.","Cash runway into 2027; three preclinical ADCs targeting 2026 IND submissions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269538","json":"https://secwatch.observer/filing/0001193125-25-269538.json","markdown":"https://secwatch.observer/filing/0001193125-25-269538.md","text":"https://secwatch.observer/filing/0001193125-25-269538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/0001193125-25-269538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/imnm-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:37:05.501733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}